Compare TNYA & AURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TNYA | AURE |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | Hong Kong |
| Employees | N/A | 4 |
| Industry | Medicinal Chemicals and Botanical Products | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.6M | 86.5M |
| IPO Year | 2021 | N/A |
| Metric | TNYA | AURE |
|---|---|---|
| Price | $0.73 | $0.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.25 | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 162.3K |
| Earning Date | 03-09-2026 | 01-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,785,569.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 434.30 |
| 52 Week Low | $0.36 | $0.23 |
| 52 Week High | $2.35 | $2.70 |
| Indicator | TNYA | AURE |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | N/A |
| Support Level | $0.70 | N/A |
| Resistance Level | $0.78 | N/A |
| Average True Range (ATR) | 0.05 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 32.66 | 0.00 |
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
Aurelion Inc is engaged in providing private wealth management and asset management services to high-net-worth and ultra-high-net-worth individuals by identifying and purchasing well-matched wealth management products offered by third-party providers. Its subsidiary operates a wealth management business that works with licensed product brokers in Hong Kong, currently consisting solely of insurance brokers distributing insurance products, and assists in customizing wealth management investment portfolios for clients. The Company generates revenue for its subsidiaries' wealth management business from product brokers in the form of referral fees, which are calculated based on the value of wealth management products purchased by clients from such brokers.